Achillion to host conference call Conference call to provide an update on the company's hepatitis C (HCV) development programs and 4Q12 earnings results will be held on February 20 at 5 pm. Webcast Link
Achillion to benefit from Bristol-Myers CRL, says FBR Capital FBR Capital expects Achillion (ACHN) to benefit from the complete response letter that the FDA sent to Bristol-Myers (BMY) on its daclatasvir HCV drug. The firm thunks the letter increases the value of GT-3 HCV patients for Achillion. FBR says that GT-3 patients constitute 5% of HCV patients in the U.S. and significantly higher in Europe. It keeps an Outperform rating on Achillion.